의사 바이러스 감염의 높은 처리량 형광 화상 진찰을 사용하여 SARS-CoV-2 중화 항체의 검출

Executive Industry Relevance

This high-throughput fluorescent imaging protocol enables rapid, cost-effective detection of SARS-CoV-2 neutralizing antibodies in convalescent serum, supporting vaccine efficacy assessment without requiring BSL-3 containment. By utilizing a VSV-based pseudovirus system in a 96-well format, the method delivers quantitative inhibition data within 24 hours, facilitating early-stage immunogenicity screening and go/no-go decisions in vaccine development pipelines. Its accessibility to standard containment level 2 labs expands assay deployment across discovery and preclinical teams, reducing bottlenecks in immune response profiling.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Measures functional antibody activity by quantifying inhibition of pseudovirus infection, providing direct evidence of neutralizing capacity beyond binding assays.
• Operational Value: Uses heat-inactivated serum samples and standardized dilution series to ensure reproducible inhibition readouts across sample sets.
• Predictive Value: Enables comparison of neutralizing titers between hospitalized and non-hospitalized convalescent patients, informing correlates of protection for vaccine design.

Screening & Assay Development

• Scientific Value: Employs EGFP-expressing pseudovirus and automated fluorescent imaging to generate focus-forming unit data for precise inhibition calculations.
• Operational Value: Compatible with multi-channel pipetting and 96-well plate formats, allowing simultaneous testing of multiple serum dilutions and controls.
• Scalability: Supports high-throughput screening of vaccine candidates or therapeutic antibodies with a 24-hour turnaround time.

Translational & Preclinical Research

• Translational Value: Uses convalescent serum from recently recovered COVID-19 patients to model human immune responses, bridging discovery to preclinical evaluation.
• Mechanistic De-risking: Assesses inhibition of spike-mediated entry, directly linking antibody function to viral neutralization mechanism.
• Continuity: Generates quantitative neutralization titers that can inform dose selection and scheduling in preclinical challenge models.

Pipeline & Workflow Integration

The method fits within the immunogenicity assessment workflow following antigen expression and preceding in vivo challenge studies, providing a functional bridge between binding antibody screens and pathogenic virus neutralization.

• Discovery Biology: Supports hypothesis testing of vaccine-induced immune responses by measuring functional antibody inhibition of viral entry.
• Screening: Delivers standardized, quantitative outputs (percent inhibition via EGFP foci counting) that enable comparison across serum samples and time points.
• Analytics: Relies on automated fluorescent imaging and focus counting to generate objective, reproducible neutralization data for downstream statistical analysis.
• Translational Research: Uses clinically relevant convalescent serum to establish benchmark neutralization levels for vaccine candidate evaluation.
• Enterprise Reuse: Establishes a reusable pseudovirus neutralization platform adaptable to emerging SARS-CoV-2 variants through spike protein pseudotyping.

Operational & Enterprise Impact

• Scientific Value: Provides mechanistic insight into antibody-mediated neutralization, reducing reliance on correlative binding assays for functional validation.
• Operational Value: Eliminates need for BSL-3 handling through pseudovirus system, enabling broader lab access and faster assay implementation.
• Strategic Value: Accelerates vaccine candidate triage by delivering neutralization data in 24 hours, supporting rapid iteration in preclinical design.
• Portfolio Impact: Enables risk-adjusted advancement decisions based on quantitative neutralization thresholds derived from convalescent patient benchmarks.

Implementation Considerations

• Requires cell culture expertise for Vero E6 maintenance and pseudovirus titering via plaque assay.
• Dependent on fluorescent imaging equipment with automated focus counting capability at 488 nm wavelength.
• Necessitates standardized serum heat inactivation (56°C, 30 min) and dilution protocols to ensure assay consistency.
• Requires biosafety level 2 facilities for handling pseudovirus and human serum samples.
• Limited to measuring inhibition of spike-dependent entry; does not assess Fc-mediated effector functions or mucosal immunity.

Biopharma FAQs